Literature DB >> 27951574

Clinical Performance Assessment of CorDiax Filters in Hemodialysis and Hemodiafiltration.

Jacky Potier, Sudhir Bowry, Bernard Canaud.   

Abstract

In this study, we evaluate the in vivo clinical performances of CorDiax FX 100 and CorDiax FX 1000 filters incorporating a high-flux membrane (Helixone Plus) designed for use in high-flux hemodialysis (HD) as well as in hemodiafiltration (HDF) in 6 stable end-stage kidney disease patients. In the HDF mode, various substitution modalities (post-, pre-, and mixed) were compared. In addition to conventional markers of efficacy of dialysis dose (urea, ionic dialysance, Kt/V), several additional middle- and large-size solute (β2-microglobulin, myoglobin, serum-free light-chain kappa and lambda, α1-microglobulin, and FGF23) compounds were explored in order to cover the spectrum of uremic toxins that are involved in uremia. A precise quantitative assessment of solute removal was performed in this study mimicking solute kinetic complexity during patient/dialysis interaction (hemoconcentration due to volume contraction, postdialysis rebound due to compartmentalization effect) in order to fit better with clinical reality and to provide clinicians more realistic estimates of solute mass transfer. The study confirms that effective solute body clearances achieved in vivo both in HD and in HDF are significantly lower than instantaneous clearances reported by manufacturers. Among dialysis modalities assessed in this study, postdilution HDF offers the most efficient modality both in terms of solute removal capacity and substitution volume used. The predilution HDF mode provides slightly but significantly lower body clearances than the postdilution mode over the spectrum of solutes assessed, a dilution factor that can be compensated for by increasing the substitution rate adequately. The clinical performance of CorDiax FX filters featuring the same highly permeable membrane engineered in 2 different configurations, one facilitating internal convective transport in HD (high internal resistance) and the other favoring high-volume on-line HDF (low internal resistance), offers interesting and effective options for enhancing removal of middle- and larger-size uremic compounds. High-volume HDF relying on different fluid substitution modes remains the more efficient modality across a large spectrum of uremic compounds tested.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27951574     DOI: 10.1159/000450810

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  8 in total

1.  Performance and Hemocompatibility of a Novel Polysulfone Dialyzer: A Randomized Controlled Trial.

Authors:  Götz Ehlerding; Ansgar Erlenkötter; Adelheid Gauly; Bettina Griesshaber; James Kennedy; Lena Rauber; Wolfgang Ries; Hans Schmidt-Gürtler; Manuela Stauss-Grabo; Stephan Wagner; Adam M Zawada; Sebastian Zschätzsch; Manuela Kempkes-Koch
Journal:  Kidney360       Date:  2021-04-07

2.  Efficacy of Supra-HFR in Removing FGF23 and Cytokines: A Single Session Analysis.

Authors:  Gabriele Donati; Andrea Angeletti; Maria Cappuccilli; Chiara Donadei; Chiara Guglielmo; Anna Scrivo; Lorenzo Gasperoni; Maddalena Zambelli; Maria Mattiotti; Gaetano La Manna
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

3.  Safety and Efficacy of Short Daily Hemodialysis with Physidia S3 System: Clinical Performance Assessment during the Training Period.

Authors:  Hafedh Fessi; Jean-Christophe Szelag; Cécile Courivaud; Philippe Nicoud; Didier Aguilera; Olivia Gilbert; Marion Morena; Michel Thomas; Bernard Canaud; Jean-Paul Cristol
Journal:  J Clin Med       Date:  2022-04-11       Impact factor: 4.964

4.  Design and methodology of the impact of HemoDiaFIlTration on physical activity and self-reported outcomes: a randomized controlled trial (HDFIT trial) in Brazil.

Authors:  Roberto Pecoits-Filho; John W Larkin; Carlos Eduardo Poli-de-Figueiredo; Américo Lourenço Cuvello Neto; Ana Beatriz Barra; Sinaia Canhada; Ludimila Guedim de Campos; Juliane Woehl; Priscila Bezerra Gonçalves; Hao Han; Thyago Proença de Moraes; Jochen G Raimann; Maria Eugenia F Canziani
Journal:  BMC Nephrol       Date:  2019-03-20       Impact factor: 2.388

5.  Toxin Removal and Inflammatory State Modulation during Online Hemodiafiltration Using Two Different Dialyzers (TRIAD2 Study).

Authors:  Gabriele Donati; Maria Cappuccilli; Chiara Donadei; Matteo Righini; Anna Scrivo; Lorenzo Gasperoni; Fulvia Zappulo; Gaetano La Manna
Journal:  Methods Protoc       Date:  2021-04-22

6.  Effect of Hemodiafiltration Versus Hemodialysis on Cognitive Function Among Patients With End-Stage Renal Disease: A Multicenter Study.

Authors:  Abdullah Kashgary; Ahlam Khojah; Boshra Bamalan; Saleha Alafari; Marah Sindi; Albandri Alahmari; Ibtisam Gasm; Lujain Alkhateeb; Yazeed Khojah; Mostafa Abdelsalam
Journal:  Cureus       Date:  2021-11-18

7.  Randomized comparison of three high-flux dialyzers during high-volume online hemodiafiltration-the comPERFORM study.

Authors:  Götz Ehlerding; Wolfgang Ries; Manuela Kempkes-Koch; Ekkehard Ziegler; Ansgar Erlenkötter; Adam M Zawada; James P Kennedy; Bertram Ottillinger; Manuela Stauss-Grabo; Thomas Lang
Journal:  Clin Kidney J       Date:  2021-10-05

8.  Randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration.

Authors:  Marion Morena; Caroline Creput; Mouloud Bouzernidj; Annie Rodriguez; Lotfi Chalabi; Bruno Seigneuric; Céline Lauret; Anne-Sophie Bargnoux; Anne-Marie Dupuy; Jean-Paul Cristol
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.